Advertisement
CORT vs TENX
Which Stock Would AI Choose? Corcept Therapeutics (CORT) vs. Tenax Therapeutics (TENX) Stock Comparison
Key Takeaways
- Corcept Therapeutics is a profitable, commercial-stage biopharmaceutical company with multiple revenue-generating drugs, while Tenax Therapeutics is a pre-revenue, development-stage company with no approved products.
- Recent market activity has diverged sharply: CORT pulled back from highs on a competitive threat, while TENX remains near multi-year lows following a failed pivotal trial.
- CORT carries a market capitalization near $9.5 billion with rising revenue guidance, whereas TENX trades as a micro-cap below roughly $110 million in market value.
- Analyst consensus for CORT is a "Buy" with an average target above $140, while TENX holds a "Moderate Buy" rating with sharply reduced targets following a Phase 3 miss.
- For more detail on each name, visit the CORT Major News and CORT Today's Price Move pages, as well as the TENX Major News and TENX Today's Price Move pages.
- To see how automated systems are positioning across the market, explore Trending AI Robots.
Introduction
This stock comparison examines two biotechnology companies at very different stages of maturity: CORT, a commercial-stage developer with approved therapies and meaningful product revenue, and TENX, a clinical-stage developer still advancing its pipeline toward potential approval. The two names sit at opposite ends of the risk spectrum, making the pairing useful for investors weighing established growth against speculative clinical exposure. Growth-oriented investors seeking proven revenue momentum may find CORT more relevant, while those evaluating high-risk, catalyst-driven biotech opportunities may scrutinize TENX. Comparing their relative performance and market positioning helps clarify how fundamental stability and binary clinical events can produce sharply different outcomes.
CORT Overview and Recent Performance
Corcept Therapeutics Incorporated is a commercial-stage biopharmaceutical company focused on medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders. Its flagship product, Korlym, treats hypercortisolism (Cushing's syndrome), and the company recently launched Lifyorli (relacorilant), approved in early 2026 for platinum-resistant ovarian cancer. In its latest reported quarter, revenue rose roughly 32% year over year to about $256 million, driven by Korlym sales and an initial contribution from Lifyorli, and management raised full-year revenue guidance to a range of $1.1 billion to $1.2 billion.
Recent weeks have been more volatile. After a strong run, shares pulled back meaningfully from their October highs as investors weighed new competitive data in the ovarian cancer space, which several financial outlets linked to a rival's Phase 3 results. Despite the pullback, the stock remains well above its 52-week low, and sell-side coverage retains a generally constructive tone, with an average price target near $141. The company also reported positive early results from a Phase 2 combination study, reinforcing its oncology pipeline momentum.
TENX Overview and Recent Performance
Tenax Therapeutics, Inc. is a development-stage pharmaceutical company advancing therapies for cardiovascular and pulmonary diseases with high unmet need. Its lead candidate, levosimendan (TNX-103), is being developed for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), a condition with no approved therapy. The company generates no product revenue and funds operations through equity financings and partnerships.
Recent market activity has been dominated by clinical results. In August, the company reported that its Phase 3 LEVEL trial did not meet its primary endpoint of improved six-minute walk distance versus placebo, nor a key secondary symptom endpoint. The announcement triggered a decline of roughly 90% in a single session, and shares have remained near multi-year lows in subsequent weeks. The outcome also prompted several analyst downgrades and meaningful price-target reductions, and the company now faces a securities class action lawsuit alleging misleading statements about the drug's prospects. With a market capitalization below roughly $110 million and a cash-burn profile, TENX's path forward depends on additional clinical work and financing.
Trending AI Robots
Tickeron offers hundreds of AI trading bots that collectively trade thousands of different tickers, but not every bot is equally suited to current market conditions. The curated Trending AI Robots section highlights only the strongest-performing and most relevant strategies for today's environment. These bots vary widely in trading style, strategy, timeframe, performance statistics, and the specific sets of tickers they trade, allowing users to align a bot's approach with their own objectives. Reviewing these curated selections can provide a useful, data-driven perspective on how automated systems are reading momentum and positioning across names like CORT and TENX. Explore the Trending AI Robots page to see which strategies are currently leading the rankings.
Head-to-Head Comparison
The contrast between these two stocks is primarily a matter of business maturity and risk profile. CORT operates a diversified, revenue-generating business spanning endocrinology and oncology, with two marketed drugs, a rising revenue outlook, and a sizable cash position of over $540 million. TENX, by contrast, is pre-revenue with a single lead asset whose pivotal trial failed, leaving its valuation tied to future clinical data and financing rather than commercial sales.
Momentum and sentiment also diverge. CORT has delivered strong year-to-date performance, though recent competitive news introduced near-term volatility and tempered short-term sentiment. TENX's market positioning deteriorated sharply after its Phase 3 miss, and its stock now trades near the bottom of its 52-week range, with downward revisions across analyst targets. Risk factors reflect the same divide: CORT faces commercial competition and pipeline execution risk, while TENX faces binary clinical, regulatory, and funding risk. Sector exposure is similar in that both are healthcare and biotechnology names, but their capital structures, profitability, and market capitalizations place them in fundamentally different investment categories.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, catalysts, and relative positioning, Tickeron's AI would likely favor CORT over TENX in the current environment. CORT benefits from positive revenue momentum, an upgraded full-year outlook, a commercialized product portfolio, and a constructive analyst consensus, even amid recent pullback. TENX, while holding a speculative upside tied to a possible clinical turnaround, currently exhibits weaker trend consistency, heightened event risk, and a diminished market position following its failed pivotal trial. These dynamics suggest CORT offers comparatively greater stability and more durable catalysts, though no outcome is guaranteed and relative positioning can shift as new data emerge.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CORT is a Hold and TENX is a Hold.
CORT sees MACD Histogram just turned negative
CORT saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 14, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 34 instances where the indicator turned negative. In 25 of the 34 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 74%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CORT as a result. In 60 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 70%.
CORT moved below its 50-day moving average on October 22, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CORT crossed bearishly below the 50-day moving average on October 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 47%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CORT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
The Aroon Indicator for CORT entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where CORT advanced for three days, in 277 of 332 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
CORT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 59 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. CORT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 76 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.146) is normal, around the industry mean (3.498). CORT's P/E Ratio (137.302) is considerably higher than the industry average of (-1.193). Projected Growth (PEG Ratio) (2.660) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (15.898) is also within normal values, averaging (440.869).
TENX's RSI Indicator ascends from oversold territory
The RSI Oscillator for TENX moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 33 similar instances when the indicator left oversold territory. In 31 of the 33 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 58 of 70 cases where TENX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
Following a +9.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where TENX advanced for three days, in 191 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
TENX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TENX as a result. In 79 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
TENX moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TENX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for TENX entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.557) is normal, around the industry mean (3.498). P/E Ratio (-1.142) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. TENX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TENX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
CORT | TENX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 57 | 4 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 100 Overvalued | 38 Fair valued | |
PROFIT vs RISK RATING 1..100 | 59 | 100 | |
SMR RATING 1..100 | 76 | 98 | |
PRICE GROWTH RATING 1..100 | 64 | 65 | |
P/E GROWTH RATING 1..100 | 9 | 98 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TENX's Valuation (38) in the Medical Specialties industry is somewhat better than the same rating for CORT (100) in the Pharmaceuticals Other industry. This means that TENX’s stock grew somewhat faster than CORT’s over the last 12 months.
CORT's Profit vs Risk Rating (59) in the Pharmaceuticals Other industry is somewhat better than the same rating for TENX (100) in the Medical Specialties industry. This means that CORT’s stock grew somewhat faster than TENX’s over the last 12 months.
CORT's SMR Rating (76) in the Pharmaceuticals Other industry is in the same range as TENX (98) in the Medical Specialties industry. This means that CORT’s stock grew similarly to TENX’s over the last 12 months.
CORT's Price Growth Rating (64) in the Pharmaceuticals Other industry is in the same range as TENX (65) in the Medical Specialties industry. This means that CORT’s stock grew similarly to TENX’s over the last 12 months.
CORT's P/E Growth Rating (9) in the Pharmaceuticals Other industry is significantly better than the same rating for TENX (98) in the Medical Specialties industry. This means that CORT’s stock grew significantly faster than TENX’s over the last 12 months.
| CORT | TENX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 86% | 2 days ago 83% |
| Momentum ODDS (%) | 2 days ago 70% | 2 days ago 86% |
| MACD ODDS (%) | 2 days ago 74% | N/A |
| TrendWeek ODDS (%) | 2 days ago 66% | 2 days ago 88% |
| TrendMonth ODDS (%) | 2 days ago 63% | 2 days ago 88% |
| Advances ODDS (%) | 3 days ago 83% | 3 days ago 82% |
| Declines ODDS (%) | 7 days ago 64% | 7 days ago 87% |
| BollingerBands ODDS (%) | 2 days ago 86% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 36% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CORT’s FA Score shows that 1 FA rating(s) are green while TENX’s FA Score has 0 green FA rating(s).
- CORT’s FA Score: 1 green, 4 red.
- TENX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CORT’s TA Score shows that 4 TA indicator(s) are bullish while TENX’s TA Score has 4 bullish TA indicator(s).
- CORT’s TA Score: 4 bullish, 6 bearish.
- TENX’s TA Score: 4 bullish, 4 bearish.
Price Growth
CORT (@Biotechnology) experienced а -10.47% price change this week, while TENX (@Biotechnology) price change was -8.15% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
CORT is expected to report earnings on Mar 02, 2027.
TENX is expected to report earnings on Apr 01, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CORT and
Correlation & Price change
A.I.dvisor indicates that over the last year, CORT has been loosely correlated with VTVT. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if CORT jumps, then VTVT could also see price increases.
| Ticker / NAME | Correlation To CORT | 1D Price Change % | ||
|---|---|---|---|---|
| CORT | 100% | -2.23% | ||
| VTVT - CORT | 49% Loosely correlated | -0.85% | ||
| TENX - CORT | 41% Loosely correlated | -5.06% | ||
| AGIO - CORT | 41% Loosely correlated | +1.21% | ||
| ARCT - CORT | 37% Loosely correlated | -1.05% | ||
| AXON - CORT | 36% Loosely correlated | -0.21% | ||
More | ||||
TENX and
Correlation & Price change
A.I.dvisor indicates that over the last year, TENX has been closely correlated with SION. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if TENX jumps, then SION could also see price increases.
| Ticker / NAME | Correlation To TENX | 1D Price Change % | ||
|---|---|---|---|---|
| TENX | 100% | -5.06% | ||
| SION - TENX | 93% Closely correlated | +3.64% | ||
| AVXL - TENX | 47% Loosely correlated | -7.38% | ||
| CORT - TENX | 41% Loosely correlated | -2.23% | ||
| HRTX - TENX | 40% Loosely correlated | +0.94% | ||
| MGNX - TENX | 32% Poorly correlated | +3.42% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IFEB | 31.45 | -0.18 | -0.58% |
| Innovator International Developed Power Buffer ETF February (IFEB) | |||
| WDI | 11.69 | -0.16 | -1.35% |
| Western Asset Diversified Income Fund | |||
| DAPP | 13.88 | -0.27 | -1.91% |
| VanEck Digital Transformation ETF (DAPP) | |||
| PSLV | 16.64 | -0.66 | -3.82% |
| Sprott Physical Silver Trust | |||
| CEGX | 12.08 | -0.79 | -6.17% |
| Tradr 2X Long CEG Daily ETF (CEGX) | |||